Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis - PubMed
4 hours ago
- #network meta-analysis
- #diabetes
- #lipid-modifying therapies
- Conducted a network meta-analysis of 18 RCTs involving 14 lipid-modifying agents and 89,717 participants with diabetes.
- Found that statins, ezetimibe, PCSK9 inhibitors, and bempedoic acid each reduced the risk of major adverse cardiovascular events (MACE).
- Atorvastatin showed strong reductions in multiple cardiovascular outcomes and revascularization risk at moderate and high doses.
- Pravastatin was associated with a significant reduction in stroke risk.
- Ezetimibe and evolocumab had comparable efficacy in reducing myocardial infarction (MI) risk.
- PCSK9 inhibitors significantly improved total cholesterol (TC) and LDL-C, with mild effects on triglycerides (TG) and HDL-C.
- Pemafibrate demonstrated pronounced benefits in TG-lowering efficacy.
- Highlighted the need for monitoring renal safety with fibrates and bempedoic acid, and glycometabolism safety with EPA-DHA.
- Provided granular evidence to support tailored lipid management strategies in diabetes.